The Global Regenerative Medicine Market is expected to grow at the highest CAGR of 16.1% from 2020 – 2027 and the market is projected to generate $ 23.7 billion by 2027.
Precedence Research, Recently Published Report on “Regenerative Medicine Market Size, Share, Growth, Trends, Segment Forecasts, Regional Outlook 2020 - 2027”. The report offers an up-to-date analysis regarding the current market scenario, latest trends, key drivers, potential challenges, profitability graph and the overall market environment.
Regenerative medicine is the division of medicine that promotes methods to repair, regrow or replace injured or diseased tissues, organs or cells. Regenerative medicine comprises of the formation and use of remedial stem cells, manufacturing of artificial organs, and tissue engineering. The combinations of tissue engineering, cell and gene therapies can strengthen the natural healing procedure in the places it is desired most, or occupy the role of a permanently injured organ. Regenerative medicine is a rather new field that connects experts in chemistry, biology, engineering, computer science, robotics, medicine, genetics and other domains to find explanations to some of the most interesting medical problems confronted by humankind.
Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1176
Growth Factors:
Factors such as increasing prevalence of chronic disorders and genetic disorders, increasing popularity of stem cells, increasing number of trauma emergencies is driving the growth of regenerative medicine market. An illness or disorder that usually persists for 3 months or longer and might get worse over a period is termed as chronic disorder. Chronic diseases mostly occur in the elderly people and can typically be controlled but not repaired. The most prevalent types of chronic ailments are heart disease, arthritis, cancer, diabetes, and stroke. Cardiovascular disorders are the biggest cause of deaths worldwide. As per the WHO data, deaths due to cardiovascular disorders represent almost 31% of the deaths globally. Almost 85% of these demises are due to stroke and heart attack. Diabetes is another most prevalent chronic ailment that affects millions of people globally. According to International Diabetes Federation (IDF), around 463 million adults (age group: 20-79 years) are battling with diabetes and by the year 2045 the number will rise to a staggering 700 million. Furthermore, approximately 75% of all health care expenses are owed to chronic ailments. Four out of the five most costly health conditions are chronic disorders such as cancer, heart disease, pulmonary conditions, and mental disorders. Regenerative medicine approaches such as stem cell therapy can cure the chronic ailments such as diabetes and arthritis, which otherwise require lifetime of medications.
The role of regenerative medicine in post trauma recovery is constantly evolving as more and more research is showing positive results. The use of regenerative medicine can be a landmark moment in the history of healthcare that will transform the treatment of chronic ailments and trauma related conditions. Thus, the high incidence of chronic ailments is driving the growth of regenerative medicine market.
Regional Analysis:
The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2019, North America dominated the global market with a market share of more than 45%. U.S. represented the highest share in the North American region primarily due to constant activity in the field of drug discovery and tissue engineering. Moreover, early adoption of latest healthcare technologies also contributed to the high market share of the United States.
Europe was the second important market chiefly due to favorable reimbursement scenario and presence of latest healthcare infrastructure. The presence of skilled researchers in the European region is also expected to boost the demand for regenerative medicine market in the near future. Asia Pacific is anticipated to grow at the maximum CAGR of around18% in the forecast period due to high incidence of trauma cases and chronic disorders. Latin America and the African and Middle Eastern region will display noticeable growth.
Report Highlights:
- Among the product segment, tissue-engineering is expected to dominate the overall market. Tissue engineering has advanced from the field of biomaterials growth and refers to the exercise of uniting cells, scaffolds, and biologically dynamic molecules into efficient tissues. The aim of tissue engineering is to accumulate functional constructs that reinstate, sustain, or progress damaged tissues or complete organs. Progenitor and stem cell therapies are expected to advance at a significant CAGR in the estimate timeframe majorly due to constantly increasing applications.
- The musculoskeletal division accounted for the largest revenue in the application segment with more than 31% share in 2019. High incidence of musculoskeletal disorders such as rheumatoid arthritis, osteoarthritis, tendinitis, and fibromyalgia is the major reason for high market share of musculoskeletal division.
- Integra Life Sciences Corporation accounted for a significant share of the global regenerative medicine market.
Key Market Players and Strategies:
The major companies operating in the worldwide regenerative medicine are Integra Life Sciences Corporation, Aspect Biosystems, Amgen, Inc., Medtronic plc, AstraZeneca, Novartis AG, Smith & Nephew plc, MiMedx Group, Shenzhen SibionoGeneTech Co., Ltd., and Baxteramong others.
High investment in the research and development along with acquisition, mergers, and collaborations are the key strategies undertaken by companies operating in the global regenerative medicine market. Recently Fuse Medical, Inc., an evolving manufacturer and supplier of innovative medical devices for the spine and orthopedic marketplace, declared the launch of FuseChoice Plus and FuseChoice Umbilical and Amniotic Membranes, and FuseChoice Plus Amniotic Joint Cushioning Fluid, the newest additions to a wide-ranging line of biologics product offerings.
Market Segmentation
By Product
- Gene Therapies
- Cell Therapies
- Tissue-Engineering
- Progenitor and Stem Cell Therapies
- Others
By Application
- Wound Care
- Musculoskeletal
- Ophthalmology
- Oncology
- Cardiovascular
- Others
By Geography
- North America
- US.
- Canada
- Europe
- Germany
- France
- United Kingdom
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. DataSources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Regenerative Medicine Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on Regenerative Medicine Market
5.1. Covid-19: Regenerative Medicine Industry Impact
5.2. Regenerative Medicine Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Regenerative Medicine Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Regenerative Medicine Market Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Regenerative Medicine Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of chronic ailments
6.1.1.2. Growing incidence of genetic disorders
6.1.2. Market Restraints
6.1.2.1. High cost of treatment
6.1.2.2. Lack of skilled manpower
6.1.3. Market Opportunities
6.1.3.1. Increasing investment in research and development
6.1.3.2. Strong product pipeline
Chapter 7. Global Regenerative Medicine Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Regenerative Medicine Market Revenue by Market Players (2016 -2019)
7.1.1.2. Regenerative Medicine Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
Chapter 8. Global Regenerative Medicine Market, By Product
8.1. Regenerative Medicine Market, by Product, 2016-2027
8.1.1. Gene Therapies
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Cell Therapies
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Tissue-Engineering
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Progenitor and Stem Cell Therapies
8.1.4.1. Market Revenue and Forecast (2016-2027)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Regenerative Medicine Market, By Application
9.1. Regenerative Medicine Market, by Application, 2016-2027
9.1.1. Wound Care
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Musculoskeletal
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Ophthalmology
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Oncology
9.1.4.1. Market Revenue and Forecast (2016-2027)
9.1.5. Cardiovascular
9.1.5.1. Market Revenue and Forecast (2016-2027)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2016-2027)
Chapter 10. Global Regenerative Medicine Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue Forecast by Product(2016-2027)
10.1.2. Market Revenue Forecast by Application(2016-2027)
10.1.3. U.S
10.1.3.1. Market Revenue Forecast (2016-2027)
10.1.4. Canada
10.1.4.1. Market Revenue Forecast (2016-2027)
10.2. Europe
10.2.1. Market Revenue Forecast by Product (2016-2027)
10.2.2. Market Revenue Forecast by Application (2016-2027)
10.2.3. UK
10.2.3.1. Market Revenue Forecast (2016-2027)
10.2.4. Germany
10.2.4.1. Market Revenue Forecast (2016-2027)
10.2.5. France
10.2.5.1. Market Revenue Forecast (2016-2027)
10.2.6. Rest of EU
10.2.6.1. Market Revenue Forecast (2016-2027)
10.3. Asia Pacific (APAC)
10.3.1. Market Revenue Forecast by Product (2016-2027)
10.3.2. Market Revenue Forecast by Application (2016-2027)
10.3.3. China
10.3.3.1. Market Revenue Forecast (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue Forecast (2016-2027)
10.3.5. Japan
10.3.5.1. Market Revenue Forecast (2016-2027)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue Forecast (2016-2027)
10.4. LATAM
10.4.1. Market Revenue Forecast by Product (2016-2027)
10.4.2. Market Revenue Forecast by Application (2016-2027)
10.4.3. Brazil
10.4.3.1. Market Revenue Forecast (2016-2027)
10.4.4. Rest of LATAM
10.4.4.1. Market Revenue Forecast (2016-2027)
10.5. Middle East and Africa (MEA)
10.5.1. Market Revenue Forecast by Product (2016-2027)
10.5.2. Market Revenue Forecast by Application (2016-2027)
10.5.3. GCC
10.5.3.1. Market Revenue Forecast (2016-2027)
10.5.4. North Africa
10.5.4.1. Market Revenue Forecast (2016-2027)
10.5.5. South Africa
10.5.5.1. Market Revenue Forecast (2016-2027)
10.5.6. Rest of MEA
10.5.6.1. Market Revenue Forecast (2016-2027)
Chapter 11. Company Profiles
11.1. Integra LifeSciences Corporation
11.1.1. Company Overview, Business Information, Regional Presence
11.1.2. Product Portfolio Analysis
11.1.2.1. ProductDetails, Specification, Application
11.1.3. Revenue, Price, and Gross Margin (2015-2020)
11.1.4. Recent Developments and Strategies
11.2. Aspect Biosystems
11.2.1. Company Overview, Business Information, Regional Presence
11.2.2. Product Portfolio Analysis
11.2.2.1. Product Details, Specification, Application
11.2.3. Revenue, Price, and Gross Margin (2015-2020)
11.2.4. Recent Developments and Strategies
11.3. Amgen, Inc.
11.3.1. Company Overview, Business Information, Regional Presence
11.3.2. Product Portfolio Analysis
11.3.2.1. Product Details, Specification, Application
11.3.3. Revenue, Price, and Gross Margin (2015-2020)
11.3.4. Recent Developments and Strategies
11.4. Medtronic plc
11.4.1. Company Overview, Business Information, Regional Presence
11.4.2. Product Portfolio Analysis
11.4.2.1. Product Details, Specification, Application
11.4.3. Revenue, Price, and Gross Margin (2015-2020)
11.4.4. Recent Developments and Strategies
11.5. AstraZeneca
11.5.1. Company Overview, Business Information, Regional Presence
11.5.2. Product Portfolio Analysis
11.5.2.1. Product Details, Specification, Application
11.5.3. Revenue, Price, and Gross Margin (2015-2020)
11.5.4. Recent Developments and Strategies
11.6. Novartis AG
11.6.1. Company Overview, Business Information, Regional Presence
11.6.2. Product Portfolio Analysis
11.6.2.1. Product Details, Specification, Application
11.6.3. Revenue, Price, and Gross Margin (2015-2020)
11.6.4. Recent Developments and Strategies
11.7. Smith & Nephew plc
11.7.1. Company Overview, Business Information, Regional Presence
11.7.2. Product Portfolio Analysis
11.7.2.1. Product Details, Specification, Application
11.7.3. Revenue, Price, and Gross Margin (2015-2020)
11.7.4. Recent Developments and Strategies
11.8. MiMedx Group
11.8.1. Company Overview, Business Information, Regional Presence
11.8.2. Product Portfolio Analysis
11.8.2.1. Product Details, Specification, Application
11.8.3. Revenue, Price, and Gross Margin (2015-2020)
11.8.4. Recent Developments and Strategies
11.9. Shenzhen SibionoGeneTech Co., Ltd.
11.9.1. Company Overview, Business Information, Regional Presence
11.9.2. Product Portfolio Analysis
11.9.2.1. Product Details, Specification, Application
11.9.3. Revenue, Price, and Gross Margin (2015-2020)
11.9.4. Recent Developments and Strategies
11.10. Baxter
11.10.1. Company Overview, Business Information, Regional Presence
11.10.2. Product Portfolio Analysis
11.10.2.1. Product Details, Specification, Application
11.10.3. Revenue, Price, and Gross Margin (2015-2020)
11.10.4. Recent Developments and Strategies
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1176
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
0 Comments